JP2015508903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508903A5 JP2015508903A5 JP2014559890A JP2014559890A JP2015508903A5 JP 2015508903 A5 JP2015508903 A5 JP 2015508903A5 JP 2014559890 A JP2014559890 A JP 2014559890A JP 2014559890 A JP2014559890 A JP 2014559890A JP 2015508903 A5 JP2015508903 A5 JP 2015508903A5
- Authority
- JP
- Japan
- Prior art keywords
- psma
- imaging
- measurement
- prostate cancer
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 63
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 45
- 238000003384 imaging method Methods 0.000 claims description 36
- 238000005259 measurement Methods 0.000 claims description 31
- 206010060862 Prostate cancer Diseases 0.000 claims description 28
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 28
- 238000002600 positron emission tomography Methods 0.000 claims description 18
- 238000011275 oncology therapy Methods 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 230000002280 anti-androgenic effect Effects 0.000 claims description 10
- 208000009956 adenocarcinoma Diseases 0.000 claims description 8
- 239000000051 antiandrogen Substances 0.000 claims description 8
- 238000002591 computed tomography Methods 0.000 claims description 7
- 108091023037 Aptamer Proteins 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000002532 enzyme inhibitor Substances 0.000 claims description 6
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 238000012634 optical imaging Methods 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 6
- 150000003384 small molecules Chemical class 0.000 claims description 6
- 239000003098 androgen Substances 0.000 claims description 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 4
- 201000007676 prostate small cell carcinoma Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 238000001794 hormone therapy Methods 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000006870 function Effects 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261604039P | 2012-02-28 | 2012-02-28 | |
| US61/604,039 | 2012-02-28 | ||
| PCT/US2013/000051 WO2013130177A1 (en) | 2012-02-28 | 2013-02-27 | Psma as a biomarker for androgen activity in prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015508903A JP2015508903A (ja) | 2015-03-23 |
| JP2015508903A5 true JP2015508903A5 (cg-RX-API-DMAC7.html) | 2016-04-14 |
Family
ID=49083148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014559890A Pending JP2015508903A (ja) | 2012-02-28 | 2013-02-27 | 前立腺癌におけるアンドロゲン活性のバイオマーカーとしてのｐｓｍａ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20130315830A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2819704A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2015508903A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2865774A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1202256A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013130177A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150131208A (ko) | 2013-03-13 | 2015-11-24 | 이미지냅 인코포레이티드 | Cd８에의 항원 결합 구조체들 |
| MX2018001566A (es) | 2015-08-07 | 2019-04-25 | Imaginab Inc | Construcciones de union a antigeno para moleculas diana. |
| JP2020505034A (ja) | 2017-01-20 | 2020-02-20 | ジュノ セラピューティクス ゲーエムベーハー | 細胞表面コンジュゲートならびに関連する細胞組成物および方法 |
| AU2018250336B2 (en) | 2017-04-07 | 2025-02-20 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods |
| CA3113080A1 (en) * | 2018-09-28 | 2020-04-02 | Imaginab, Inc. | Cd8 imaging constructs and methods of use thereof |
| WO2022114675A1 (ko) * | 2020-11-24 | 2022-06-02 | 한국과학기술연구원 | 전립선암 진단을 위한 바이오마커, 이들의 조합, 및 이의 용도 |
| EP4267969A4 (en) * | 2020-12-22 | 2025-02-12 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF PROSTATE CANCER |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE337011T1 (de) * | 2001-02-07 | 2006-09-15 | Beth Israel Hospital | Modifizierte psma-liganden und deren verwendung |
| AU2007227195A1 (en) * | 2006-03-21 | 2007-09-27 | The Regents Of The University Of California | N-cadherin and Ly6 E: targets for cancer diagnosis and therapy |
| EP2209498A2 (en) * | 2007-10-03 | 2010-07-28 | Cornell University | Treatment of proliferative disorders using antibodies to psma |
| US20100047166A1 (en) * | 2008-08-20 | 2010-02-25 | Kanner Steven B | Antibodies and related molecules that bind to 58p1d12 proteins |
| EP2398504B1 (en) * | 2009-02-17 | 2018-11-28 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| EP4420730A3 (en) * | 2009-03-19 | 2024-11-13 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
| WO2010119001A1 (en) * | 2009-04-14 | 2010-10-21 | Institut Gustave Roussy | Prostate cancer cell lines and their use in screening method |
| EP2817629A4 (en) * | 2012-02-24 | 2016-01-13 | Univ Cornell | INCREASED PSMA VALUE AS IDENTIFIER OF DEADLY PROSTATE CANCER |
-
2013
- 2013-02-27 HK HK15102796.5A patent/HK1202256A1/xx unknown
- 2013-02-27 WO PCT/US2013/000051 patent/WO2013130177A1/en not_active Ceased
- 2013-02-27 JP JP2014559890A patent/JP2015508903A/ja active Pending
- 2013-02-27 US US13/778,306 patent/US20130315830A1/en not_active Abandoned
- 2013-02-27 EP EP13754565.3A patent/EP2819704A4/en not_active Withdrawn
- 2013-02-27 CA CA2865774A patent/CA2865774A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015508903A5 (cg-RX-API-DMAC7.html) | ||
| Brody et al. | Chemokine receptor 2–targeted molecular imaging in pulmonary fibrosis. A clinical trial | |
| Avril et al. | Monitoring response to treatment in patients utilizing PET | |
| Ellingson et al. | Pros and cons of current brain tumor imaging | |
| McMahon et al. | Investigating the effects of dexamethasone on blood-brain barrier permeability and inflammatory response following focused ultrasound and microbubble exposure | |
| Hodgson | Late effects in the era of modern therapy for Hodgkin lymphoma | |
| Gerstner et al. | Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib | |
| Ascierto et al. | MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study | |
| Schlumberger et al. | ENDOCRINE TUMOURS: approach to the patient with advanced differentiated thyroid cancer | |
| Walker et al. | Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression? | |
| Taguchi et al. | CT texture analysis for the prediction of KRAS mutation status in colorectal cancer via a machine learning approach | |
| Plouznikoff et al. | Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients | |
| Chow et al. | Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma | |
| Zhang et al. | Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus | |
| Horn et al. | FDG and FLT-PET for early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma | |
| Di Ianni et al. | Sex dependence of opioid-mediated responses to subanesthetic ketamine in rats | |
| Chen et al. | Mesenchymal stem cells combined with hepatocyte growth factor therapy for attenuating ischaemic myocardial fibrosis: assessment using multimodal molecular imaging | |
| Ammari et al. | Radiological evaluation of response to treatment: application to metastatic renal cancers receiving anti-angiogenic treatment | |
| Guo et al. | Imaging tumor response following liver-directed intra-arterial therapy | |
| JP2009538415A5 (cg-RX-API-DMAC7.html) | ||
| Gordon et al. | Hyperpolarized 13C metabolic MRI of patients with pancreatic ductal adenocarcinoma | |
| Yavuz et al. | Factors affecting survival in glioblastoma patients below and above 65 years of age: A retrospective observational study | |
| Nguyen et al. | Revolutionizing brain tumor care: Emerging technologies and strategies | |
| Hanbury et al. | Pathology of fractionated whole-brain irradiation in rhesus monkeys (Macaca mulatta) | |
| Mooney et al. | Bexotegrast shows dose-dependent integrin αvβ6 receptor occupancy in lungs of participants with idiopathic pulmonary fibrosis: a phase 2, open-label clinical trial |